Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSC) Net Income (2020 - 2025)

Ensysce Biosciences (ENSC) has disclosed Net Income for 6 consecutive years, with -$3.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Net Income fell 684.92% to -$3.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$11.1 million, a 39.4% decrease, with the full-year FY2024 number at -$8.0 million, up 27.56% from a year prior.
  • Net Income was -$3.7 million for Q3 2025 at Ensysce Biosciences, down from -$1.8 million in the prior quarter.
  • In the past five years, Net Income ranged from a high of $640683.0 in Q3 2024 to a low of -$16.9 million in Q3 2021.
  • A 5-year average of -$3.8 million and a median of -$2.7 million in 2023 define the central range for Net Income.
  • Peak YoY movement for Net Income: plummeted 2623.52% in 2021, then soared 123.6% in 2024.
  • Ensysce Biosciences' Net Income stood at -$2.1 million in 2021, then plummeted by 192.41% to -$6.2 million in 2022, then skyrocketed by 43.11% to -$3.5 million in 2023, then fell by 2.48% to -$3.6 million in 2024, then fell by 4.47% to -$3.7 million in 2025.
  • Per Business Quant, the three most recent readings for ENSC's Net Income are -$3.7 million (Q3 2025), -$1.8 million (Q2 2025), and -$2.0 million (Q1 2025).